Advancing Innovative Botanical Therapies for Neurological and Inflammatory Diseases
We are advancing a pipeline of innovative, multi-target botanical therapies to address neurodegenerative and inflammatory diseases. Our lead candidate, CNR-401, represents a critical step toward delivering safe, effective treatments for underserved patient populations.
CNR-401: Innovating Neurodegenerative Care
CNR-401 is a novel, multi-target botanical therapy developed for ALS and other Motor Neuron Diseases. It aims to slow disease progression, improve symptoms, and enhance quality of life through a synergistic approach.
​
In preclinical models, CNR-401 has demonstrated neuroprotective effects and a reduction in neuroinflammation, key drivers of disease progression in ALS.
​
Entering clinical trials in 2026, CNR-401 represents a new therapeutic strategy for patients with limited treatment options.
CNR-100s: Inflammation
Canurta’s CNR-100 candidates are focused on tackling chronic inflammatory conditions such as rheumatoid arthritis, juvenile arthritis, and respiratory diseases. These therapies inhibit two key inflammatory pathways—mPGES-1 and 5-LO—to provide dual inhibition and block the production of proinflammatory molecules.
CNR-400s: Neurology
Canurta’s CNR-400 candidates target neurodegenerative diseases like ALS, Alzheimer’s, and FTD by inhibiting enzymes (MAGL and FAAH) that contribute to inflammation. By protecting brain cells from inflammatory damage, these therapies hold significant promise for slowing disease progression and improving quality of life.
Canurta's Pipeline